Alkermes plc (ALKS)

The total asset value of Alkermes plc (ALKS) stood at $ 2,416 Mln as on 31-Mar-23

The share price of Alkermes plc (ALKS) is $24.22 (NASDAQ) as of 27-Nov-2023 16:00 EST. Alkermes plc (ALKS) has given a return of 9.53% in the last 3 years.

Alkermes plc (ALKS) has a market capitalisation of $ 5,239 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Alkermes plc (ALKS) is 4.04 times as on 09-Jun-2023, a 0.59% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Alkermes plc (ALKS) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alkermes plc (ALKS) and enter the required number of quantities and click on buy to purchase the shares of Alkermes plc (ALKS).

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

The CEO & director of Mr. Richard F. Pops. is Alkermes plc (ALKS), and CFO & Sr. VP is Mr. Iain Michael Brown.

The promoters of Alkermes plc (ALKS) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of Alkermes plc (ALKS) was $-164 Mln.